Novel advancements in the management of hepatocellular carcinoma in 2008.

By J. Llovet, Jordi Bruix1 , 2. Journal of Hepatology, 2008

866 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. (2012, background): “Surgical resection is widely accepted as curative treatment for most of the patients with small HCC, who are unwilling to receive liver transplantations [4,5].”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “This trend is expected to continue growing in parallel to the wider implementation of surveillance policies in developed countries [102].”
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012, background): “This trend is expected to continue growing in parallel to the wider implementation of surveillance policies in developed countries [102].”
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial , (2012, background): “therapies [1,2], and up to 70% of patients who undergo these procedures will have recurrent disease within 5 years and reach a more advanced tumor stage [4,5].”
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, background): “Chemoembolization increases the median survival of these patients to 19–20 months according to RCTs and metaanalysis of pooled data, and is considered the standard of care [333, 343].”